Pfizer/Warner Pro Forma Accounting Shows 1.5% Margin Benefit From Lipitor
Executive Summary
Pfizer/Warner-Lambert's pro forma operating margins will be 1.5 percentage points closer to the Pfizer level after the elimination of double-counting of Lipitor sales.
You may also be interested in...
Pfizer/Pharmacia Merger Review: Firms Expect Second-Request From FTC
The Federal Trade Commission review of the Pfizer/Pharmacia merger should progress relatively smoothly because the same FTC reviewers worked with Pfizer on the Warner-Lambert deal, CEO Hank McKinnell told the Bear Stearns healthcare conference in New York City Sept. 17
Pharmacia To Launch Parecoxib With Zyvox Sales Force: No Partner Needed
Pharmacia plans to launch the injectable COX-2 inhibitor parecoxib using the hospital sales force that launched the antibiotic Zyvox (linezolid), Global Business Management President Carrie Cox said during an Oct. 30 earnings conference call.
Pharmacia To Launch Parecoxib With Zyvox Sales Force: No Partner Needed
Pharmacia plans to launch the injectable COX-2 inhibitor parecoxib using the hospital sales force that launched the antibiotic Zyvox (linezolid), Global Business Management President Carrie Cox said during an Oct. 30 earnings conference call.